SCHEMBL7984475

SCHEMBL7984475

CC(C)(Oc1ccc(Cl)cc1)c1nnc(-c2ccncc2Br)o1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.40
NPSR1 Q6W5P4 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HPGD P15428 4/20 0.34
CYP1A2 P05177 3/20 0.34
CYP3A4 P08684 3/20 0.34
CYP2C19 P33261 3/20 0.34
CYP2C9 P11712 2/20 0.34
MAPK1 P28482 2/20 0.34
CYP2D6 P10635 2/20 0.34
NPC1 O15118 4/20 0.34
RAB9A P51151 4/20 0.34
TP53 P04637 1/20 0.34
GAA P10253 1/20 0.34
FLT1 P17948 4/20 0.34
KDR P35968 4/20 0.34
KDM4E B2RXH2 2/20 0.32
ALDH1A1 P00352 2/20 0.32
MAPT P10636 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7977891 0.88 CYP1A2 (0.36) TSHRNPSR1HPGDCYP1A2CYP3A4
SCHEMBL1418141 0.77 KDR (0.39) NPSR1TDP1L3MBTL1HPGDNPC1
SCHEMBL7985174 0.74 LMNA (0.37) CYP1A2CYP3A4CYP2C19CYP2C9CYP2D6
SCHEMBL7977879 0.71 KDR (0.39) NPSR1TDP1HPGDNPC1RAB9A
SCHEMBL7981272 0.64 HSD11B1 (0.40) CYP1A2CYP3A4CYP2C19CYP2C9CYP2D6
SCHEMBL18448572 0.64 GCGR (0.43) HPGDNPC1RAB9AKDRKDM4E
SCHEMBL10144693 0.62 RAB9A (0.54) TSHRNPSR1L3MBTL1HPGDMAPK1
SCHEMBL30702143 0.61 NPC1 (0.43) TSHRNPSR1TDP1L3MBTL1HPGD
SCHEMBL20360599 0.61 NPC1 (0.43) TSHRNPSR1TDP1L3MBTL1HPGD
SCHEMBL7981149 0.60 CYP1A2 (0.56) TSHRNPSR1TDP1HPGDCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8377923-B2 Triazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2013-02-19 US disclosed
US-8377923-B2 Triazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2013-02-19 US disclosed
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2011-05-05 US disclosed
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2011-05-05 US disclosed
WO-2010001946-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF アステラス製薬株式会社 (JP) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF HSD11B1, HSD11B2, HSD3B1 TSHR 690/4885NPSR1 1240/4885TDP1 812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.